Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Cancer -Related Legislation Introduced

August 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

HR1579, introduced by Rep. Brown (D-OH), to require providers of home infusion therapy to be licensed and to limit physician referrals for home infusion therapy services in which the physician has a financial interest.

  • HR1579, introduced by Rep. Brown (D-OH), to require providersof home infusion therapy to be licensed and to limit physicianreferrals for home infusion therapy services in which the physicianhas a financial interest.
  • HR1614, introduced by Rep. Durbin (D-IL), to amend provisionsof Title XVIII of the Social Security Act relating to Medigappolicies to eliminate age rating in premiums.
  • HR1668, introduced by Rep. Danner (D-MO), to establish a programto control fraud and abuse in the Medicare program, and to increasethe amount of civil monetary penalties that may be assessed againstindividuals and entities committing fraud against Medicare.
  • S827, introduced by Sen. Pressler (R-SD), to amend the InternalRevenue Code of 1986 to limit an employer's deduction for health-carecosts of its employees if the employer fails to honor its commitmentto provide care to retirees.
  • S863, introduced by Sen. Grassley (R-IA), to amend Title XVIIIof the Social Security Act to provide for increased Medicare reimbursementfor physician assistants, to increase the delivery of health servicesin areas that have a shortage of health professionals.
  • S872, introduced by Sen. Bond (R-MO), to provide for establishmentof a modernized and simplified health information network foruse by Medicare and Medicaid.
Articles in this issue

Physicians Take Aim at Localized Prostate Cancer Treatment Controversy in 'Shootout'
CA 125 Predicts Response to Chemo in Ovarian Ca
Biochemical Modulation Promising in RT-Resistant GI Cancer
Cancer Institute of NJ Adds to its Staff
A Century of Breast Cancer Litigation Is 'Deconstructed'
New Depot Formulation of LHRH Analogue Allows 12-Week Dosing
NSABP Investigation Threatens Academic Freedom for All: Fisher
Cancer Fax Directory in 3rd Edition
HIV-Related Malignancies Increasing, Physicians Tell Panel
Breast Cancer Risk Factors Remain Elusive Target
Conference Celebrates 100 Years of Radiology
Coalition Promotes Worksite Cancer Screening
Search for Ovarian Cancer Screen Must Look Beyond Ultrasound
DNA Defects Predict Endometrial Ca Prognosis
Cost Studies Help Determine Best BMT Use
Recent Videos
4 experts in this video
4 experts in this video
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Related Content
Advertisement

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC

Roman Fabbricatore
August 22nd 2025
Article

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Multivariate analysis showed that females had an increased risk of progressive disease vs males.

Serplulimab plus Chemotherapy Improves OS and PFS in Elderly ES-SCLC

Tim Cortese
August 22nd 2025
Article

The biomarker NLR may not be suitable for prognosis prediction in elderly patients with small cell lung cancer, according to this real-world study.


Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.


First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

Ariana Pelosci
August 21st 2025
Article

The confirmed ORR was 40.0% in cohort 1A and 66.7% in cohort 1B of patients treated with sacituzumab tirumotecan/tagitanlimab for advanced NSCLC.


Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 21st 2025
Article

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.

Related Content
Advertisement

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients with Stage III CRC

Roman Fabbricatore
August 22nd 2025
Article

Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.


Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 18th 2025
Podcast

Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.


Multivariate analysis showed that females had an increased risk of progressive disease vs males.

Serplulimab plus Chemotherapy Improves OS and PFS in Elderly ES-SCLC

Tim Cortese
August 22nd 2025
Article

The biomarker NLR may not be suitable for prognosis prediction in elderly patients with small cell lung cancer, according to this real-world study.


Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 14th 2025
Podcast

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.


First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

Ariana Pelosci
August 21st 2025
Article

The confirmed ORR was 40.0% in cohort 1A and 66.7% in cohort 1B of patients treated with sacituzumab tirumotecan/tagitanlimab for advanced NSCLC.


Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.

Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

Tim Cortese
August 21st 2025
Article

TTFields plus chemotherapy significantly prolonged overall survival compared with chemotherapy alone in patients with pancreatic cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.